Current concepts in biomarker technology for bladder cancers

Clinical Chemistry

Volumn 46, Issue 5, 2000, Pages 595-605

  Burchardt, Martin ^a,b   Burchardt, Tatjana ^a   Shabsigh, Ahmad ^a   De La Taille, Alexandre ^a   Benson, Mitchell C ^a   Sawczuk, Ihor ^a,c  

^a Coll of Phys/Surgs of Columbia U ^*  (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD GROUP ANTIGEN; CELL ADHESION MOLECULE; CYCLINE; EPIDERMAL GROWTH FACTOR; FIBRIN; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; HYALURONIC ACID; HYALURONIDASE; INTEGRIN; KI 67 ANTIGEN; MEMBRANE ANTIGEN; NERVE CELL ADHESION MOLECULE; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN;

BLADDER CANCER; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER STAGING; CELL CYCLE; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LABORATORY TEST; LATEX AGGLUTINATION TEST; ONCOGENE; PRACTICE GUIDELINE; REVIEW; TRANSITIONAL CELL CARCINOMA;

EID: 0034036723     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.5.595     Document Type: Review

References (121)

1. 1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. 2. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997;13:291-8.
3. 3. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology 1995;45:387-96.
4. 4. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997;15:84-8.
5. 5. Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-80.
6. 6. de Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder cancer. Oncology 1998;12:1717-23.
7. 7. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin N Am 1998;25:661-76.
8. 8. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-9.
9. 9. Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987;60:1423-7.
10. 10. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974;60:1410-7.
11. 11. Berezney R. The nuclear matrix: a heuristic model for investigating genomic organization and function in the cell nucleus. J Cell Biochem 1991;47:109-23.
12. 12. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-7.
13. 13. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996;156: 1280-5.
14. 14. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999;161:62-5.
15. 15. Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998;52:793-6.
16. 16. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997;31: 163-8.
17. 17. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Excfusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7.
18. 18. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al. A multicenter trial evaluation of the fibrin/ fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997;158:801-5.
19. 19. McCabe RP, Lamm DL, Haspel MV, Pomato N, Smith KO, Thompson E, Hanna MG Jr. A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of urinary fibrin(ogen) degradation products. Cancer Res 1984;44:5886-93.
20. 20. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997;158:2098-101.
21. 21. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ. RE: comparison of screening methods in the detection of bladder cancer. J Urol 1997;161:388-94.
22. 22. Sarosdy MF. The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 1997;15:103-6.
23. 23. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Espasa A, Chinchilla V, Soria F. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder. J Urol 1999;161:1110-5.
24. 24. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999;161:443-6.
25. 25. Conn IG, Crocker J, Wallace DM, Hughes MA, Hilton CJ. Basement membranes in urothelial carcinoma. Br J Urol 1987;60: 536-42.
26. 26. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, de Vere White R, Sheinfeld J, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997;50:349-53.
27. 27. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997;50:882-7.
28. 28. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45:472-7.
29. 29. Heicappell R, Wettig IC, Schostak M, Muller M, Steiner U, Sauter T, Miller K. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999;35:81-7.
30. 30. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990;345:458-60.
31. 31. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-73.
32. 32. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992;89:10114-8.
33. 33. Blackburn EH. Telomerases. Annu Rev Biochem 1992;61:113-29.
34. 34. Greaves M. Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Trends Genet 1996;12: 127-8.
35. 35. Pathak S, Wang Z, Dhaliwal MK, Sacks PC. Telomeric association: another characteristic of cancer chromosomes? Cytogenet Cell Genet 1988;47:227-9.
36. 36. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998; 82:708-14.
37. 37. Landman J, Kavaler E, Droller MJ, Liu BC. Applications of telomerase in urologic oncology. World J Urol 1997;15:120-4.
38. 38. Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362-9.
39. 39. Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89: 724-30.
40. 40. Dalbagni G, Han W, Zhang ZF, Cordon-Cardo C, Saigo P, Fair WR, et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 1997;3:1593-8.
41. 41. Csoka TB, Frost GI, Stern R. Hyaluronidases in tissue invasion. Invasion Metastasis 1997;17:297-311.
42. 42. Lokeshwar VB, Soloway MS, Block NL. Secretion of bladder tumor-derived hyaluronidase activity by invasive bladder tumor cells. Cancer Lett 1998;131:21-7.
43. 43. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997;57:778-83.
44. 44. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. ImmunoCyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9.
45. 45. Koss LG, Czerniak B, Herz F, Wersto RP. Flow cytometric measurements of DNA and other cell components in human tumors: a critical appraisal. Hum Pathol 1989;20:528-48.
46. 46. Schapers RF, Ploem-Zaaijer JJ, Pauwels RP, Smeets AW, van den Brandt PA, Tanke HJ, Bosman FT. Image cytometric DNA analysis in transitional cell carcinoma of the bladder. Cancer 1993;72: 182-9.
47. 47. Melamed MR. Flow cytometry of the urinary bladder. Urol Clin N Am 1984;11:599-608.
48. 48. Mora LB, Nicosia SV, Pow-Sang JM, Ku NK, Diaz JI, Lockhart J, Einstein A. Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients. J Urol 1996;156:49-54.
49. 49. Blomjous EC, Schipper NW, Baak JP, Vos W, De Voogt HJ, Meijer CJ. The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. Am J Clin Pathol 1989;91:243-8.
50. 50. Saracino GA, Ditonno P, Disabato G, Traficante A, Battaglia M, Lucivero G, Selvaggi FP. Prediction of recurrence and progression in primary superficial bladder cancer with DNA flow cytometry. Eur Urol 1992;21(Suppl 1):26-30.
51. 51. Campanella R, Russo A, Plaja S, Bazan V, Pavone C, Corselli G, Pavone-Macaluso M. Study of cellular DNA content by flow cytometry in primary bladder carcinomas. Significance of monoclonal and multiclonal varieties of DNA aneuploidy. Eur Urol 1992;21:58-63.
52. 52. Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H, Marberger M. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998;159:265-9.
53. 53. Carter HB, Amberson JB, Bander NH, Badalament R, Gorelick J, Vaughan ED Jr, Whitmore WF Jr. Newer diagnostic techniques for bladder cancer. Urol Clin N Am 1987;14:763-9.
54. 54. Parry WL, Hemstreet GP 3rd. Cancer detection by quantitative fluorescence image analysis. J Urol 1988;139:270-4.
55. 55. Kamentsky LA, Kamentsky LD. Microscope-based multiparameter laser scanning cytometer yielding data comparable to flow cytometry data. Cytometry 1991;12:381-7.
56. 56. Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res 1985;45:2405-14.
57. 57. Coon JS, Weinstein RS, Summers JL. Blood group precursor T-antigen expression in human urinary bladder carcinoma. Am J Clin Pathol 1982;77:692-9.
58. 58. Huben RP. Tumor markers in bladder cancer. Urology 1984;23(3 Suppl):10-4.
59. 59. Cordon-Cardo C, Reuter VE, Lloyd KO, Sheinfeld J, Fair WR, Old LJ, Melamed MR. Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. Cancer Res 1988;48:4113-20.
60. 60. Malmstrom PU, Busch C, Norlen BJ, Andersson B. Expression of ABH blood group isoantigen as a prognostic factor in transitional cell bladder carcinoma. Scand J Urol Nephrol 1988;22:265-70.
61. 61. Golijanin D, Sherman Y, Shapiro A, Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 1995;46:173-7.
62. 62. Sheinfeld J, Reuter VE, Melamed MR, Fair WR, Morse M, Sogani PC, et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 1990; 143:285-8.
63. 63. Fradet Y, Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol 1993;11:145-53.
64. 64. Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt™. Can J Urol 1997;4:400.
65. 65. Allard P, Fradet Y, Tetu B, Bernard P. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995;1:1195-202.
66. 66. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
67. 67. Okamura K, Miyake K, Koshikawa T, Asai J. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J Urol 1990;144:875-8.
68. 68. Fontana D, Bellina M, Gubetta L, Fasolis G, Rolle L, Scoffone C, et al. Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J Urol 1992;148:1149-51.
69. 69. Cohen MB, Waldman FM, Carroll PR, Kerschmann R, Chew K, Mayall BH. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol 1993;24:772-8.
70. 70. Tsujihashi H, Nakanishi A, Matsuda H, Uejima S, Kurita T. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol 1991;145:846-9.
71. 71. Mulder AH, Van Hootegem JC, Sylvester R, ten Kate FJ, Kurth KH, Ooms EC, Van der Kwast TH. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 1992;166:37-43.
72. 72. Bush C, Price P, Norton J, Parkins CS, Bailey MJ, Boyd J, et al. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br J Cancer 1991;64:357-60.
73. 73. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol 1996;155:316-20.
74. 1 grade 3 carcinoma of the bladder. J Urol 1992;148:1420-6.
75. 75. Chen G, Lin MS, Li RC. Expression and prognostic value of proliferating cell nuclear antigen in transitional cell carcinoma of the urinary bladder. Urol Res 1997;25:25-30.
76. 76. Kroft SH, Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Lab Investig 1994;71:158-74.
77. 77. Fontana D, Bellina M, Scoffone C, Cagnazzi E, Cappia S, Cavallo F, et al. Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur Urol 1996;29:470-6.
78. 78. Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993;53:133-9.
79. 79. Czerniak B, Deitch D, Simmons H, Etkind P, Herz F, Koss LG. Ha-ras gene codon 12 mutation and DNA ploidy in urinary bladder carcinoma. Br J Cancer 1990;62:762-3.
80. 80. Del Senno L, Maestri I, Piva R, Hanau S, Reggiani A, Romano A, Russo G. Differential hypomethylation of the c-myc protooncogene in bladder cancers at different stages and grades. J Urol 1989;142:146-9.
81. 81. Masters JR, Vesey SG, Munn CF, Evan GI, Watson JV. c-myc oncoprotein levels in bladder cancer. Urol Res 1988;16:341-4.
82. 82. Lipponen PK. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol 1995;175:203-10.
83. 83. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;18:7288-93.
84. 84. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994;86:1325-30.
85. 85. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu WJ, et al. Oncogene amplification in urothelial cancers with p53gene mutation or MDM2 amplification. J Natl Cancer Inst 1994;86: 1331-5.
86. 86. Shiina H, Igawa M, Shigeno K, Yamasaki Y, Urakami S, Yoneda T, et al. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 1999;56:239-47.
87. 87. Lamph WW, Wamsley P, Sassone-Corsi P, Verma IM. Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature 1988;334: 629-31.
88. 88. Sassone-Corsi P, Lamph WW, Kamps M, Verma IM. fos-associated cellular p39 is related to nuclear transcription factor AP-1. Cell 1988;54:553-60.
89. 89. Tiniakos DG, Mellon K, Anderson JJ, Robinson MC, Neal DE, Horne CH. c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. Br J Urol 1994;74:757-61.
90. 90. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530-7.
91. 91. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-30.
92. 92. Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A. HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J 1989;8:167-73.
93. 93. Gorgoulis VG, Barbatis C, Poulias I, Karameris AM. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol 1995;8:758-64.
94. 94. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70:2493-8.
95. 95. Moriyama M, Akiyama T, Yamamoto T, Kawamoto T, Kato T, Sato K, et al. Expression of c-erbB-2 gene product in urinary bladder cancer. J Urol 1991;145:423-7.
96. 96. Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 1993;29A:749-53.
97. 97. Mellon JK, Lunec J, Wright C, Home CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996;155:321-6.
98. 98. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-5.
99. 99. Mattila AL, Saario I, Viinikka L, Ylikorkala O, Perheentupa J. Urinary epidermal growth factor concentrations in various human malignancies. Br J Cancer 1988;57:139-41.
100. 100. Kristensen JK, Lose G, Lund F, Nexo E. Epidermal growth factor in urine from patients with urinary bladder tumors. Eur Urol 1988;14:313-4.
101. 101. Fuse H, Mizuno I, Sakamoto M, Katayama T. Epidermal growth factor in urine from the patients with urothelial tumors. Ural Int 1992;48:261-4.
102. 102. Messing EM, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology 1994;44:502-6.
103. 103. Ravery V, Grignon D, Angulo J, Pontes E, Montie J, Crissman J, Chopin D. Evaluation of epidermal growth factor receptor, transforming growth factor α, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997;25: 9-17.
104. 104. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281-5.
105. 105. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999;161:799-804.
106. 106. Coombs LM, Pigott DA, Eydmann ME, Proctor AJ, Knowles MA. Reduced expression of TGF β is associated with advanced disease in transitional cell carcinoma. Br J Cancer 1993;67: 578-84.
107. 107. Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S, Kamidono S. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998;123:121-6.
108. 108. Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol 1997;157:2351-5.
109. 109. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988;48:2083-8.
110. 110. Gazzaniga P, Gandini O, Gradilone A, Silvestri I, Giuliani L, Magnanti M, et al. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses. Int J Oncol 1999;14:1123-7.
111. 111. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356-61.
112. 112. Mialhe A, Louis J, Pasquier D, Rambeaud JJ, Seigneurin D. Expression of three cell adhesion molecules in bladder carcinomas: correlation with pathological features. Anal Cell Pathol 1997;13:125-36.
113. 113. Harabayashi T, Kanai Y, Yamada T, Sakamoto M, Ochiai A, Kakizoe T, et al. Reduction of integrin β4 and enhanced migration on laminin in association with intraepithelial spreading of urinary bladder carcinomas. J Urol 1999;161:1364-71.
114. 114. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
115. 115. Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
116. 116. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
117. 117. Bochner BH, Esrig D, Groshen S, Dickinson M, Weidner N, Nichols PW, et al. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer. Clin Cancer Res 1997;3:1615-22.
118. 118. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
119. 119. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54:3391-5.
120. 120. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-6.
121. 121. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256-61.